Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lecomkafusp Alfa · WTX-124

Recombinant protein · Immune activation, directed at Interleukin-2 receptor (high-affinity IL-2 receptor on CD8+ T cells and NK cells (IL2RA) · developed by Werewolf Therapeutics

Phase 1 Most advanced trial (none active)
HOWL Developer
1 Registered trials

What is Lecomkafusp Alfa?

Lecomkafusp alfa is a prodrug form of interleukin-2 (IL-2) with an inactivation domain linked by a tumor protease-sensitive linker and a half-life extension domain. IL-2 is released in the tumor microenvironment, where it binds high-affinity IL-2 receptors on CD8+ T cells and NK cells to activate them against tumor cells. It is being studied in metastatic and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
WTX-124
Drug type
Recombinant protein
Targets
Interleukin-2 receptor (high-affinity IL-2 receptor on CD8+ T cells and NK cells (IL2RA)
Mechanism
Immune activation, directed at Interleukin-2 receptor (high-affinity IL-2 receptor on CD8+ T cells and NK cells (IL2RA)
Pathways
IL2R-mediated signaling, CD8+ T-cell and NK cell activation and expansion, tumor cell cytolysis
Therapy area
Oncology
Developer
Werewolf Therapeutics, Inc. (HOWL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
HA9RQB7ML6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05479812 Phase 1 Metastatic Solid Tumor Completed HOWL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorMetastatic Solid Tumor

Other drugs acting on IL2RA

More from Werewolf Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HOWL page.

Follow HOWL, the company behind Lecomkafusp Alfa

See HOWL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HOWL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.